Solvay renews drug development partnership

Solvay Pharmaceuticals has announced the renewal of its clinical development partnership with Quintiles for another five years.

The alliance was first signed in 2001 and has seen the completion of three phase III clinical testing programs, produced decisive data at phase II that resulted in the cessation of two redundant programs and the moving of two compounds from phase II to phase III trials sooner than expected.

Quintiles’ IIIb-IV capabilities have also been added to the partnership.

Werner Cautreels, chief executive officer of Solvay Pharmaceuticals, said: “Using Quintiles’ global infrastructure and experts as a strategic asset, we’ve advanced projects at a much faster rate than we could have achieved alone and with greater flexibility.”

He added that in the next five years of the partnership, the company aimed to accomplish greater levels of efficiency, savings and speed.

Earlier this year, Solvay Pharmaceuticals signed an additional agreement with Besins International for the global expansion of its AndroGel male hormone treatment product.